TP53 and liver cancer: Based on our evidence, liver cancers that retain wild-type p53, for example, may be more likely to usefully respond to MDM2 E3 inhibition than pancreatic cancers, where the sensitivity to on-target toxicity in acinar cells from genotoxic combination therapy may be high.